Solanezumab Promising in Mild Alzheimer’s, But Program Still Very Risky: Analyst

Eli Lilly’s Alzheimer’s disease candidate solanezumab may offer potential as a treatment for milder forms of the disease, new detailed data reveal, but the company’s prospects are still flimsy, with odds of failure potentially exceeding more than 50 percent, one analyst says. The drug reduced cognitive decline by 34 percent in a secondary analysis of pooled data from mild Alzheimer’s patients in the two pivotal studies, a statistically significant result, Lilly said.
Drug Industry Daily